The presence of the superfamily members of the ATP binding cassette (ABC) transporters is well established as the main cause of multidrug resistance, since they efflux therapeutic compounds from cells and reduce the intracellular drug levels.
Full cell functionality after transportation.
Worldwide shipments at room temperature thanks to our patented technology.
Validation data available and high quality-control standards.
Ready-to-use uptake proteins for Drug-Transporter assays
MATE1 transporter expression
PreadyTake MATE1 contains HEK293 cells transfected with the SLC47A1 gene to overexpress the drug and toxin transporter1 (MATE1). This is a membrane transporter of clinical importance for assessing drug-transporter interactions at preclinical stages.
MATE1 transporter localizes apically in the liver and kidney and plays an important role in the renal disposition and elimination of drugs, especially in the renal elimination of metformin and the renal toxicity of cisplatin.
In vitro assays of the uptake transporter are performed with cell lines stably expressing pharmacologically relevant human transmembrane receptors. Drug-transporter interaction involving the drug candidate as a substrate or as an inhibitor of the transporter protein is assessed by comparing compound accumulation in cells overexpressing the transmembrane protein and nonspecific accumulation in those expressing the empty vector (termed HEK-MOCK cells or HEK-WT cells).
The recent FDA regulatory guideline now recommends evaluation of MATE1-mediated drug interactions for NMEs that undergo significant renal elimination.
OCT2 transporter expression
PreadyTake OCT2 contains HEK293 cells transfected with the SLC22A2 gene to overexpress organic cation transporter-2 (OCT2), a primarily renal uptake transporter expressed on the basolateral (blood) side of proximal tubule cells.
OCT2 is a membrane transporter of significant clinical relevance for assessing drug-transporter interactions at preclinical stages. It plays a key role in the renal clearance and disposition of primarily cationic drugs and endogenous compounds. It works together with MATE1, which facilitates the elimination of OCT2 substrates in the urine.
Current FDA and EMA guidelines recommend evaluation of OCT2 liabilities for drugs with high renal clearance, or that are likely to be coadministered with OCT2 substrates, such as metformin. Simultaneous evaluation of MATE drug-drug interactions is also advisable.
ReadyCell Uptake TRANSPORTER kits
Our plates overexpressing uptake transporters allow the study of drug renal clearance and biliary excretion.
Our 96 multiwell insert plates with differentiated MATE1 and OCT2-overexpressing HEK293 cells are relevant to study drug-transporter interaction according to regulatory recommendations.
Frequently Asked Questions
Is the quality control data specific for each kit?
Yes, we provide a concrete quality control for each batch so the customer can have a reference for the kit before and after shipment.
Does ReadyCell shipping medium affect HEK293 cell line?
No, ReadyCell’s Shipping Medium consists of a semi-solid culture system specifically designed to preserve cells at room temperature (15-25ºC). This medium maintains a suitable physicochemical environment, keeping adequate moisture conditions for cellular homeostasis and forming a protective cushion that protects cell integrity and functionality during long-distance shipments up to seven days.
What do the current regulations establish on the basis of Uptake Transporter tests?
According to the European and the American Regulatory Agencies (EMA and FDA), evaluation of MATE1 and OCT2 liabilities for drugs clearance are recommended.
What are the recommended reference compounds for MATE1 and OCT2?
In the case of MATE1, Metformin is recommended as substrate and Quinidine as inhibitor, all of them in transport buffer solution. For OCT2, the recommended substrate is 1-methyl-4-phenylpyridinium iodide (MPP+) while the inhibitor for OCT2 is Doxepin, also in transport buffer solution.